# A Study of ZL-1310 in Participants With Selected Solid Tumors

Source: https://onco.cc/trials/nct06885281/  
OnCo record `nct06885281` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ZL-1310 in advanced solid tumours, run by Zai Lab (Shanghai) Co., Ltd., now recruiting.

## Summary

A Study of ZL-1310 in Participants With Selected Solid Tumors is a phase 1/2 interventional study registered as NCT06885281 by Zai Lab (Shanghai) Co., Ltd., with 166 participants planned, started 2025-05-12 and due to reach its primary completion in 2027-08. Interventions recorded: ZL-1310.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06885281
- Phase: 1/2
- Setting: A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
- Sponsor: Zai Lab (Shanghai) Co., Ltd.
- Enrolled: 166

## Sources

- ClinicalTrials.gov NCT06885281: https://clinicaltrials.gov/study/NCT06885281

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [ZL-1310](https://onco.cc/drugs/zl-1310/)
- companies: [Zai Lab](https://onco.cc/companies/zai-lab/)

---
JSON: https://onco.cc/api/v1/entities/nct06885281.json